{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009837","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.283650+00:00","generated_at":"2026-06-17T09:24:43.379997+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivos Therapeutics reports Q4 revenue $4.0M, FY revenue $16.0M; appliance sales up 21% in Q4","bullets":["Q4 2022 revenue $4.0M vs $4.4M YoY; full-year revenue $16.0M vs $16.9M; $2.5M revenue deferred under ASC 606.","Q4 appliance arches sold 2,938 (+21% YoY); full-year 12,281 (+8% YoY).","Gross margin 60% in Q4 (vs 71% YoY) and 63% for FY (vs 75% YoY) due to higher costs and new incentives.","Cash $3.5M at Dec 31, 2022; raised ~$7.4M net in Jan 2023 private placement.","Received FDA 510(k) clearance for DNA appliance for mild-to-moderate OSA; acquired patents from Advanced Facialdontics for TMD/Bruxism."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009837","json":"https://secwatch.observer/filing/0001493152-23-009837.json","markdown":"https://secwatch.observer/filing/0001493152-23-009837.md","text":"https://secwatch.observer/filing/0001493152-23-009837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223009837/0001493152-23-009837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223009837/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:24:43.379997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2914a352e9df0129eab41c4660e4dc4a29a0a928","claim":"Vivos Therapeutics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $4.0 million for the fourth quarter of 2022 and $16.0 million for the full year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223009837/0001493152-23-009837-index.htm","confidence":0.65,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$4.0 million for the fourth quarter of 2022 and $16.0 million for the full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}